FI972709A0 - Substituoituja imideja TNF-inhibiittoreina - Google Patents
Substituoituja imideja TNF-inhibiittoreinaInfo
- Publication number
- FI972709A0 FI972709A0 FI972709A FI972709A FI972709A0 FI 972709 A0 FI972709 A0 FI 972709A0 FI 972709 A FI972709 A FI 972709A FI 972709 A FI972709 A FI 972709A FI 972709 A0 FI972709 A0 FI 972709A0
- Authority
- FI
- Finland
- Prior art keywords
- tnf inhibitors
- substituted imides
- imides
- inhibitors
- substituted
- Prior art date
Links
- 150000003949 imides Chemical class 0.000 title abstract 2
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 title 1
- 239000002451 tumor necrosis factor inhibitor Substances 0.000 title 1
- GODXRDNLVMRFSG-GFCCVEGCSA-N 2-[(2r)-1-(3,4-dimethoxyphenyl)propan-2-yl]isoindole-1,3-dione Chemical group C1=C(OC)C(OC)=CC=C1C[C@@H](C)N1C(=O)C2=CC=CC=C2C1=O GODXRDNLVMRFSG-GFCCVEGCSA-N 0.000 abstract 1
- 206010006895 Cachexia Diseases 0.000 abstract 1
- 206010014824 Endotoxic shock Diseases 0.000 abstract 1
- 206010040070 Septic Shock Diseases 0.000 abstract 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000010076 replication Effects 0.000 abstract 1
- 241001430294 unidentified retrovirus Species 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/366,679 US6429221B1 (en) | 1994-12-30 | 1994-12-30 | Substituted imides |
PCT/US1995/015384 WO1996020926A1 (en) | 1994-12-30 | 1995-11-20 | Substituted imides as tnf inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
FI972709A0 true FI972709A0 (fi) | 1997-06-23 |
FI972709A FI972709A (fi) | 1997-08-29 |
Family
ID=23444039
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FI972709A FI972709A (fi) | 1994-12-30 | 1997-06-23 | Substituoituja imideja TNF-inhibiittoreina |
Country Status (20)
Country | Link |
---|---|
US (3) | US6429221B1 (fi) |
EP (1) | EP0800514B1 (fi) |
JP (1) | JP4118329B2 (fi) |
KR (2) | KR20040007729A (fi) |
AT (1) | ATE337301T1 (fi) |
AU (1) | AU709719B2 (fi) |
CA (1) | CA2208671C (fi) |
CZ (1) | CZ203697A3 (fi) |
DE (1) | DE69535195T2 (fi) |
DK (1) | DK0800514T3 (fi) |
ES (1) | ES2271948T3 (fi) |
FI (1) | FI972709A (fi) |
HK (1) | HK1004674A1 (fi) |
HU (1) | HUT77124A (fi) |
NZ (1) | NZ297324A (fi) |
PL (1) | PL185361B1 (fi) |
PT (1) | PT800514E (fi) |
RU (1) | RU2162078C2 (fi) |
SK (1) | SK86897A3 (fi) |
WO (1) | WO1996020926A1 (fi) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5703098A (en) * | 1994-12-30 | 1997-12-30 | Celgene Corporation | Immunotherapeutic imides/amides |
US5728844A (en) * | 1995-08-29 | 1998-03-17 | Celgene Corporation | Immunotherapeutic agents |
DE69700616T2 (de) * | 1996-07-02 | 2000-03-16 | Nisshin Flour Milling Co., Ltd. | Imid derivate |
ES2315435T3 (es) * | 1996-08-12 | 2009-04-01 | Celgene Corporation | Nuevos agentes inmunoterapeuticos y su uso para la reduccion de los niveles de citoquinas. |
WO1998007421A1 (fr) * | 1996-08-16 | 1998-02-26 | Ishihara Sangyo Kaisha, Ltd. | Composition medicinale |
EP0933360A1 (en) | 1997-12-22 | 1999-08-04 | Pharmachemie B.V. | Synthesis of new beta-lactams |
ES2138561B1 (es) * | 1998-04-17 | 2000-07-01 | Univ Madrid Complutense | Uso de los peptidos vip y pacap en el tratamiento del shock endotoxico en mamiferos. |
US6808902B1 (en) | 1999-11-12 | 2004-10-26 | Amgen Inc. | Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules |
US6667316B1 (en) * | 1999-11-12 | 2003-12-23 | Celgene Corporation | Pharmaceutically active isoindoline derivatives |
US6326388B1 (en) * | 1999-12-21 | 2001-12-04 | Celgene Corporation | Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha level |
US8030343B2 (en) | 2000-06-08 | 2011-10-04 | Celgene Corporation | Pharmaceutically active isoindoline derivatives |
US7091353B2 (en) | 2000-12-27 | 2006-08-15 | Celgene Corporation | Isoindole-imide compounds, compositions, and uses thereof |
US7320991B2 (en) | 2001-02-27 | 2008-01-22 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health | Analogs of thalidomide as potential angiogenesis inhibitors |
AU2002257195A1 (en) * | 2001-04-23 | 2002-11-05 | University Of Virginia Patent Foundation | Synthesis and evaluation of novel phthalimide mimics as anti-angiogenic agents |
DK2270052T3 (en) | 2001-06-26 | 2018-07-02 | Amgen Inc | Antibodies to OPGL |
US7498171B2 (en) | 2002-04-12 | 2009-03-03 | Anthrogenesis Corporation | Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
AU2003234624B8 (en) * | 2002-05-17 | 2009-03-12 | Celgene Corporation | Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases |
US20100129363A1 (en) * | 2002-05-17 | 2010-05-27 | Zeldis Jerome B | Methods and compositions using pde4 inhibitors for the treatment and management of cancers |
KR20050056247A (ko) * | 2002-10-15 | 2005-06-14 | 셀진 코포레이션 | 골수형성이상증후군의 치료 및 관리를 위한 선택적인사이토킨 저해 약물의 사용 방법 및 이를 포함하는 조성물 |
US20040087558A1 (en) * | 2002-10-24 | 2004-05-06 | Zeldis Jerome B. | Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain |
US7776907B2 (en) * | 2002-10-31 | 2010-08-17 | Celgene Corporation | Methods for the treatment and management of macular degeneration using cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide |
CA2505131A1 (en) | 2002-11-06 | 2004-05-27 | Celgene Corporation | Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases |
NZ540384A (en) * | 2002-11-06 | 2008-06-30 | Celgene Corp | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myeloproliferative diseases |
AU2003294311B8 (en) * | 2002-11-18 | 2008-06-05 | Celgene Corporation | Method of using and compositions comprising (+)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide |
US20040167199A1 (en) * | 2002-11-18 | 2004-08-26 | Celgene Corporation | Methods of using and compositions comprising (-)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide |
DE60330187D1 (de) | 2002-12-30 | 2009-12-31 | Celgene Corp | Fluoralkoxy-substituierte 1, 3-dihydro-isoindolyl-verbindungen und ihre pharmazeutischen verwendungen |
US20040175382A1 (en) * | 2003-03-06 | 2004-09-09 | Schafer Peter H. | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system |
CA2538864C (en) | 2003-09-17 | 2013-05-07 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Thalidomide analogs as tnf-alpha modulators |
US8952895B2 (en) | 2011-06-03 | 2015-02-10 | Apple Inc. | Motion-based device operations |
US20050142104A1 (en) * | 2003-11-06 | 2005-06-30 | Zeldis Jerome B. | Methods of using and compositions comprising PDE4 modulators for the treatment and management of asbestos-related diseases and disorders |
WO2005051942A1 (en) | 2003-11-19 | 2005-06-09 | Signal Pharmaceuticals, Llc | Indazole compounds and methods of use thereof as protein kinase inhibitors |
CN1918838B (zh) | 2004-02-13 | 2012-02-01 | 松下电器产业株式会社 | 发送装置、接收装置及无线通信方法 |
EP1744748A4 (en) * | 2004-04-14 | 2009-08-12 | Celgene Corp | METHOD FOR USE OF SELECTIVE CYTOKINE-INHIBITORY MEDICAMENTS AND COMPOSITIONS CONTAINING THEREOF FOR THE TREATMENT AND SUPPLY OF MYELODYSPLASTIC SYNDROMES |
CN1972684A (zh) * | 2004-04-23 | 2007-05-30 | 细胞基因公司 | 用于治疗和控制肺高血压的含有pde4调节剂的组合物以及其使用方法 |
US20070190070A1 (en) * | 2004-09-03 | 2007-08-16 | Zeldis Jerome B | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system |
CN101052630A (zh) | 2004-09-03 | 2007-10-10 | 细胞基因公司 | 取代的杂环化合物和其用途 |
WO2006050057A2 (en) * | 2004-10-28 | 2006-05-11 | Celgene Corporation | Methods and compositions using pde4 modulators for treatment and management of central nervous system injury |
US20080138295A1 (en) * | 2005-09-12 | 2008-06-12 | Celgene Coporation | Bechet's disease using cyclopropyl-N-carboxamide |
PE20120580A1 (es) | 2009-02-10 | 2012-05-23 | Celgene Corp | Metodos para utilizar y composiciones que comprenden moduladores pde4 para tratamiento, prevencion y control de tuberculosis |
CA2794096A1 (en) | 2010-04-07 | 2011-10-13 | Celgene Corporation | Methods for treating respiratory viral infection |
JP2013531499A (ja) | 2010-06-15 | 2013-08-08 | セルジーン コーポレイション | 乾癬の治療のためのバイオマーカー |
US8927725B2 (en) | 2011-12-02 | 2015-01-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Thio compounds |
US20170087129A1 (en) | 2014-05-16 | 2017-03-30 | Celgene Corporation | Compositions and methods for the treatment of atherosclerotic cardiovascular diseases with pde4 modulators |
WO2017070291A1 (en) | 2015-10-21 | 2017-04-27 | Celgene Corporation | Pde4 modulators for treating and preventing immune reconstitution inflammatory syndrome (iris) |
Family Cites Families (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3536809A (en) * | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
US3598123A (en) * | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US3845770A (en) * | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3916899A (en) * | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
US4008719A (en) * | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
US4215114A (en) * | 1976-11-12 | 1980-07-29 | The Upjohn Company | Analgesic N-[2-(furyl-methylamino and 2-thienylmethylamino)cycloaliphatic]be |
IE58110B1 (en) * | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
US5073543A (en) * | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
IT1229203B (it) * | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
US5120548A (en) * | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
KR0166088B1 (ko) * | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
US5733566A (en) * | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
US5580578A (en) * | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
JPH0625163A (ja) * | 1992-07-03 | 1994-02-01 | Ube Ind Ltd | N−(ジメトキシベンジル)フタルイミド類およびその製造法 |
WO1994008976A1 (en) * | 1992-10-08 | 1994-04-28 | E.I. Du Pont De Nemours And Company | Fungicidal and miticidal aminopyrimidines |
US5591767A (en) * | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
US5629327A (en) * | 1993-03-01 | 1997-05-13 | Childrens Hospital Medical Center Corp. | Methods and compositions for inhibition of angiogenesis |
US5541213A (en) * | 1993-06-24 | 1996-07-30 | Eisai Co., Ltd. | Propenoic acid derivatives diazole propenoic acid compounds which have useful pharmaceutical utility |
US5463063A (en) | 1993-07-02 | 1995-10-31 | Celgene Corporation | Ring closure of N-phthaloylglutamines |
US5698579A (en) * | 1993-07-02 | 1997-12-16 | Celgene Corporation | Cyclic amides |
US5605914A (en) * | 1993-07-02 | 1997-02-25 | Celgene Corporation | Imides |
RO118291B1 (ro) * | 1993-11-30 | 2003-04-30 | Searle & Co | Derivati de pirazol 1,3,4,5 - tetrasubstituiti si compozitie farmaceutica care ii contine |
IT1270594B (it) * | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
US5703098A (en) * | 1994-12-30 | 1997-12-30 | Celgene Corporation | Immunotherapeutic imides/amides |
US5801195A (en) * | 1994-12-30 | 1998-09-01 | Celgene Corporation | Immunotherapeutic aryl amides |
US5703092A (en) * | 1995-04-18 | 1997-12-30 | The Dupont Merck Pharmaceutical Company | Hydroxamic acid compounds as metalloprotease and TNF inhibitors |
US5728845A (en) | 1995-08-29 | 1998-03-17 | Celgene Corporation | Immunotherapeutic nitriles |
US5728844A (en) * | 1995-08-29 | 1998-03-17 | Celgene Corporation | Immunotherapeutic agents |
US5658940A (en) * | 1995-10-06 | 1997-08-19 | Celgene Corporation | Succinimide and maleimide cytokine inhibitors |
US5635517B1 (en) * | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
US6281230B1 (en) * | 1996-07-24 | 2001-08-28 | Celgene Corporation | Isoindolines, method of use, and pharmaceutical compositions |
JP4065567B2 (ja) | 1996-07-24 | 2008-03-26 | セルジーン コーポレイション | 置換2―(2,6―ジオキソピペリジン―3―イル)フタルイミド類及び―1―オキソイソインドリン類ならびにTNFαレベルの減少方法 |
HU228769B1 (en) | 1996-07-24 | 2013-05-28 | Celgene Corp | Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha |
US5798368A (en) * | 1996-08-22 | 1998-08-25 | Celgene Corporation | Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels |
ES2315435T3 (es) * | 1996-08-12 | 2009-04-01 | Celgene Corporation | Nuevos agentes inmunoterapeuticos y su uso para la reduccion de los niveles de citoquinas. |
CZ299873B6 (cs) | 1997-07-31 | 2008-12-17 | Celgene Corporation | Derivát hydroxamové kyseliny a farmaceutický prostredek s jeho obsahem |
US5874448A (en) * | 1997-11-18 | 1999-02-23 | Celgene Corporation | Substituted 2-(2,6 dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing TNFα levels |
US5955476A (en) * | 1997-11-18 | 1999-09-21 | Celgene Corporation | Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels |
SE9803710L (sv) | 1998-09-25 | 2000-03-26 | A & Science Invest Ab | Användning av vissa substanser för behandling av nervrotsskador |
US6020358A (en) * | 1998-10-30 | 2000-02-01 | Celgene Corporation | Substituted phenethylsulfones and method of reducing TNFα levels |
KR100672892B1 (ko) * | 1999-03-18 | 2007-01-23 | 셀진 코오퍼레이션 | 치환된 1-옥소- 및 1,3-디옥소이소인돌린스 및 염증성사이토킨 수치를 감소시키기 위한 약학적 조성물로서의이들의 사용 |
US6667316B1 (en) | 1999-11-12 | 2003-12-23 | Celgene Corporation | Pharmaceutically active isoindoline derivatives |
US6699899B1 (en) | 1999-12-21 | 2004-03-02 | Celgene Corporation | Substituted acylhydroxamic acids and method of reducing TNFα levels |
US6326388B1 (en) * | 1999-12-21 | 2001-12-04 | Celgene Corporation | Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha level |
US20030045552A1 (en) | 2000-12-27 | 2003-03-06 | Robarge Michael J. | Isoindole-imide compounds, compositions, and uses thereof |
-
1994
- 1994-12-30 US US08/366,679 patent/US6429221B1/en not_active Expired - Fee Related
-
1995
- 1995-11-20 SK SK868-97A patent/SK86897A3/sk unknown
- 1995-11-20 EP EP95940847A patent/EP0800514B1/en not_active Expired - Lifetime
- 1995-11-20 KR KR10-2003-7016455A patent/KR20040007729A/ko not_active Application Discontinuation
- 1995-11-20 JP JP52098696A patent/JP4118329B2/ja not_active Expired - Fee Related
- 1995-11-20 DE DE69535195T patent/DE69535195T2/de not_active Expired - Lifetime
- 1995-11-20 AU AU42463/96A patent/AU709719B2/en not_active Ceased
- 1995-11-20 DK DK95940847T patent/DK0800514T3/da active
- 1995-11-20 RU RU97112858/04A patent/RU2162078C2/ru not_active IP Right Cessation
- 1995-11-20 PL PL95321065A patent/PL185361B1/pl not_active IP Right Cessation
- 1995-11-20 KR KR1019970704510A patent/KR100466838B1/ko not_active IP Right Cessation
- 1995-11-20 CA CA002208671A patent/CA2208671C/en not_active Expired - Fee Related
- 1995-11-20 PT PT95940847T patent/PT800514E/pt unknown
- 1995-11-20 AT AT95940847T patent/ATE337301T1/de not_active IP Right Cessation
- 1995-11-20 HU HU9701849A patent/HUT77124A/hu unknown
- 1995-11-20 NZ NZ297324A patent/NZ297324A/xx not_active IP Right Cessation
- 1995-11-20 CZ CZ972036A patent/CZ203697A3/cs unknown
- 1995-11-20 ES ES95940847T patent/ES2271948T3/es not_active Expired - Lifetime
- 1995-11-20 WO PCT/US1995/015384 patent/WO1996020926A1/en active IP Right Grant
-
1997
- 1997-06-23 FI FI972709A patent/FI972709A/fi unknown
-
1998
- 1998-02-17 HK HK98101231A patent/HK1004674A1/xx not_active IP Right Cessation
-
2002
- 2002-03-25 US US10/105,833 patent/US6844359B2/en not_active Expired - Fee Related
-
2004
- 2004-11-16 US US10/989,945 patent/US7329761B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
HK1004674A1 (en) | 1998-12-04 |
KR20040007729A (ko) | 2004-01-24 |
US6429221B1 (en) | 2002-08-06 |
PL185361B1 (pl) | 2003-04-30 |
SK86897A3 (en) | 1998-01-14 |
US7329761B2 (en) | 2008-02-12 |
DK0800514T3 (da) | 2006-12-27 |
NZ297324A (en) | 2000-03-27 |
WO1996020926A1 (en) | 1996-07-11 |
DE69535195T2 (de) | 2007-07-12 |
CA2208671C (en) | 2009-02-10 |
DE69535195D1 (de) | 2006-10-05 |
FI972709A (fi) | 1997-08-29 |
EP0800514A1 (en) | 1997-10-15 |
US20020143027A1 (en) | 2002-10-03 |
ATE337301T1 (de) | 2006-09-15 |
US20050090516A1 (en) | 2005-04-28 |
PT800514E (pt) | 2006-12-29 |
JP4118329B2 (ja) | 2008-07-16 |
AU4246396A (en) | 1996-07-24 |
RU2162078C2 (ru) | 2001-01-20 |
KR980700968A (ko) | 1998-04-30 |
AU709719B2 (en) | 1999-09-02 |
CZ203697A3 (en) | 1997-11-12 |
JPH10511946A (ja) | 1998-11-17 |
PL321065A1 (en) | 1997-11-24 |
CA2208671A1 (en) | 1996-07-11 |
EP0800514B1 (en) | 2006-08-23 |
HUT77124A (hu) | 1998-03-02 |
KR100466838B1 (ko) | 2005-09-02 |
ES2271948T3 (es) | 2007-04-16 |
US6844359B2 (en) | 2005-01-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK0800514T3 (da) | Substituerede imider som TNF inhibitorer | |
DE69522961D1 (en) | Immunotherapeutische arylamide | |
PT862552E (pt) | Succinimidas e maleimidas inibidoras de citocinas | |
ATE259787T1 (de) | Inhibitoren des tumor-necrosis-factors | |
EP1004572A3 (en) | Amines as inhibitors of TNF alpha | |
EA199700186A1 (ru) | Новые дипептидные амидины, используемые в качестве ингибиторов тромбина | |
NO986103L (no) | Substituerte indazol-derivater og deres anvendelse som fosfodiesterase (PDE)type IV - og tumornekrose-faktor (TNF)inhibitorer | |
NO991048D0 (no) | Indazolderivater og deres anvendelse som inhibitorer av fosfodiesterase (PDE) type IV og fremstillingen av tumornekrosefaktor (TNF) | |
ATE114467T1 (de) | (+)-alpha-(2,3 dimethoxyphenyl)-1-(2- (fluorophenyl)ethyl>-4-piperidinmethanol. | |
DK0726899T3 (da) | Nye pyrazincarboxamidderivater, deres fremstilling og deres anvendelse i lægemidler | |
NO953763L (no) | Heterocykel-holdige amidin-derivater, deres fremstilling og anvendelse | |
DK0572537T3 (da) | Cytokinnhibitorer | |
DK0797437T3 (da) | Immunterapeutiske imider/amider samt anvendelse deraf til at reducere niveauer af TNFalfa | |
DK360189A (da) | S-adenosyl-methionin-decarboxylase-inhibitorer, deres fremstilling og anvendelse | |
GB8926611D0 (en) | Compound and its use | |
SU1489146A1 (ru) | 1-(4-Тиоцианатофенил)-5-(2-фурил)-3-этил-Δ-пиразолин, проявляющий противовоспалительную и анальгетическую активность |